Neuropsychiatric and Neurodevelopmental Disorders: Harnessing Rare Variants
Jan 01–04, 2024 | Location to be Determined
Scientific Organizers:
Jennifer G. Mulle, Audrey Thurm, Christa L. Martin and Carrie E. Bearden
Jan 01–04, 2024 | Location to be Determined
Scientific Organizers:
Jennifer G. Mulle, Audrey Thurm, Christa L. Martin and Carrie E. Bearden
Available Formats:
Supported by the Directors' Fund
Important Deadlines
Early Registration Deadline:
Deadlines not yet available for this meeting.
Scholarship Deadline:
Deadlines not yet available for this meeting.
Global Health Award Deadline:
Deadlines not yet available for this meeting.
Short Talk Abstract Deadline:
Deadlines not yet available for this meeting.
Poster Abstract Deadline:
Deadlines not yet available for this meeting.
Meeting Summary
# Genetics, Genomics and RNA
# Neurobiology
This is an unprecedented time in psychiatric genetics. There are now hundreds of rare genetic variants that are strongly associated with neuropsychiatric traits and psychiatric diseases. Many individual teams are making progress studying a given gene or genomic interval, and the time is right for knowledge transfer across teams. This conference is driven by three emerging concepts. First, the discovery of rare variants with large effects for neuropsychiatric disorders provides a new avenue for understanding the underlying mechanisms of more common disorders. Second, these rare variants are often associated with multiple neurodevelopmental or neuropsychiatric disorders, suggesting that there are common underlying biological pathways that confer susceptibility to disease; this finding simultaneously suggests that genetic and epigenetic modifiers play a key role in determining the phenotype of specific individuals. Third, large scale collaborative efforts and harmonized frameworks for data collection are starting to enable more fine-grained, quantitative and even longitudinal phenotyping of probands and relatives, allowing us to move beyond the relatively gross characterization of categorical Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnoses. These new findings underscore the need for interaction between geneticists, neurobiologists and clinical scientists, and this meeting sets the stage for such cross-cutting collaborations.
SPECIAL RECOGNITION:
KEYSTONE SYMPOSIA THANKS OUR SPONSOR(S) FOR GENEROUSLY SUPPORTING THIS MEETING:
KEYSTONE SYMPOSIA THANKS OUR MEETING EXHIBITOR(S):
KEYSTONE SYMPOSIA THANKS THESE DONOR(S) FOR GENEROUSLY SUPPORTING THIS MEETING:
THESE COMPANIES HAVE GENEROUSLY AGREED TO COVER THE EXPENSES OF THEIR EMPLOYEES WHO ARE SPEAKING AT THIS MEETING:
GRANT RECOGNITION:
KEYSTONE SYMPOSIA THANKS OUR GIFT-IN-KIND MEDIA SPONSORS
Subscribe for Updates